Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 17254476 | Small-Molecule HIV-1 Capsid Protein Inhibitors and Methods Using Same | December 2020 | May 2024 | Abandon | 41 | 0 | 1 | No | No |
| 17057392 | GIP ELEVATION INHIBITOR | November 2020 | April 2024 | Abandon | 41 | 1 | 0 | No | No |
| 17056803 | AGI-134 COMBINED WITH A CHECKPOINT INHIBITOR FOR THE TREATMENT OF SOLID TUMORS | November 2020 | April 2024 | Abandon | 41 | 1 | 0 | No | No |
| 17056303 | PULVERIZED PRODUCT OF CARBOXYMETHYLATED PULP AND ADDITIVE CONTAINING SAID PULVERIZED PRODUCT | November 2020 | May 2024 | Abandon | 42 | 1 | 0 | No | No |
| 17041164 | CYCLIC DINUCLEOTIDE COMPOUNDS CONTAINING 2-AZA-HYPOXANTHINE OR 6H-PYTAZOLO[1,5-D][1,2,4]TRIZAIN-7-ONE AS STRING AGONISTS | September 2020 | June 2022 | Abandon | 20 | 1 | 0 | No | No |
| 17017937 | METHOD FOR MITIGATION OF NON-ALCOHOLIC FATTY LIVER DISEASE BY USE OF A COMPOSITION COMPRISING SMALL-MOLECULE FUCOIDAN AND FUCOXANTHIN | September 2020 | July 2023 | Abandon | 34 | 3 | 0 | No | No |
| 16967086 | NOVEL SMALL MOLECULE DRUG CONJUGATES OF GEMCITABINE DERIVATIVES | August 2020 | October 2022 | Abandon | 26 | 1 | 0 | No | No |
| 16929716 | SYNTHETIC METHODS FOR PREPARATION OF (S)-(2R,3R,11BR)-3-ISOBUTYL-9,10-DIMETHOXY-2,3,4,6,7,11B-HEXAHYDRO-1H-PYRIDO[2,1,-A]lSOQUINOLIN-2-YL 2-AMINO-3-METHYLBUTANOATE DI(4-METHYLBENZENESULFONATE) | July 2020 | January 2022 | Abandon | 18 | 2 | 0 | Yes | Yes |
| 16876539 | ANTHOCYANIDIN COMPLEX | May 2020 | June 2023 | Abandon | 37 | 2 | 1 | No | No |
| 16871140 | COMBINATION THERAPY FOR CANCER | May 2020 | August 2021 | Allow | 16 | 2 | 0 | Yes | No |
| 16760901 | METHODS AND COMPOSITIONS FOR TREATING ACUTE MYELOID LEUKEMIA | April 2020 | May 2024 | Abandon | 48 | 2 | 1 | No | Yes |
| 16757759 | METHOD FOR PREPARING HIGH-PURITY TOTAL GINKGOLIDE AND USE THEREOF | April 2020 | February 2022 | Abandon | 22 | 1 | 0 | No | No |
| 16848708 | Use of Timosaponin Enzymatically Transformed Product in Preparation of Drugs for Inhibiting Skin Superficial Fungi | April 2020 | June 2023 | Abandon | 38 | 2 | 0 | No | No |
| 16833280 | METHOD FOR TREATING LIVER DISEASE BY ADMINISTERING PHARMACEUTICAL COMPOSITION COMPRISING CATECHOL DERIVATIVE | March 2020 | March 2022 | Abandon | 23 | 2 | 0 | No | No |
| 16648658 | Method and Agent for Enhancing Performance and Flow of Solids | March 2020 | July 2023 | Abandon | 40 | 1 | 1 | No | No |
| 16811016 | BIOBASED SUPERABSORBENT HYDROGELS | March 2020 | October 2023 | Abandon | 43 | 2 | 0 | No | No |
| 16724046 | HOMOGENEOUS POLYSACCHARIDE ESP-B4, DERIVED FROM HERBA EPHEDRA, PREPARATION METHOD AND MEDICAL USE THEREOF | December 2019 | April 2023 | Abandon | 40 | 2 | 1 | No | No |
| 16615223 | NICOTINAMIDE ADENINE DINUCLEOTIDE ANALOGUES | November 2019 | October 2022 | Abandon | 35 | 1 | 0 | No | No |
| 16500325 | ACTIVATION OF P2X7 RECEPTORS WITH NON-BZBZ ADENOSINE TRIPHOSPHATE DERIVATIVES | October 2019 | August 2022 | Abandon | 35 | 1 | 0 | No | No |
| 16587551 | DIET THERAPY OF INTRACTABLE CANCER AND MEDICAL DIET SUITABLE THEREFOR | September 2019 | October 2023 | Abandon | 48 | 4 | 0 | No | No |
| 16509552 | SYNTHETIC METHODS FOR PREPARATION OF (S)-(2R,3R,11bR)-3-ISOBUTYL-9,10-DIMETHOXY-2,3,4,6,7,11b-HEXAHYDRO-1H-PYRIDO[2,1-a]ISOQUINOLIN-2-YL 2-AMINO-3-METHYLBUTANOATE DI(4-METHYLBENZENESULFONATE) | July 2019 | March 2022 | Abandon | 32 | 2 | 0 | Yes | Yes |
| 16469656 | Three dimensional printing with biomaterial | June 2019 | May 2024 | Abandon | 59 | 1 | 1 | No | No |
| 16413513 | PERFLUOROCARBYLATED COMPOUNDS FOR THE NON-VIRAL TRANSFER OF NUCLEIC ACIDS | May 2019 | July 2022 | Abandon | 38 | 1 | 0 | No | No |
| 16391918 | PHOSPHATE-CROSSLINKED STARCH NANOPARTICLES AND USE FOR DRUG DELIVERY | April 2019 | November 2023 | Abandon | 55 | 4 | 1 | No | No |
| 16334251 | USE OF TYROSINE-KINASE INHIBITOR IN PREPARING PHARMACEUTICAL PRODUCT FOR CANCER TREATMENT | March 2019 | January 2022 | Abandon | 34 | 6 | 0 | Yes | No |
| 16312828 | CANCER TREATMENT AND METASTASIS INHIBITION USING AN ANTI-CANCER STEM CELL AGENT IN COMBINATION WITH A NEU1 SIALIDASE INHIBITOR OR A CYTOKINE INHIBITOR AFTER PRIMARY CANCER TREATMENT | December 2018 | October 2023 | Abandon | 58 | 4 | 0 | No | No |
| 16304538 | 6-THIO-2'-DEOXYGUANOSINE (6-THIO-DG) RESULTS IN TELOMERASE DEPENDENT TELOMERE DYSFUNCTION AND CELL DEATH IN VARIOUS MODELS OF THERAPY-RESISTANT CANCER CELLS | November 2018 | September 2023 | Abandon | 57 | 4 | 0 | No | Yes |
| 15745552 | COMPOSITION CONTAINING NAD FOR PREVENTING AND TREATING OBESITY OR IMPAIRED GLUCOSE TOLERANCE | January 2018 | July 2023 | Abandon | 60 | 8 | 0 | No | No |
| 15329647 | Treatment of Glycosylation Deficiency Diseases | January 2017 | November 2021 | Abandon | 58 | 4 | 0 | Yes | Yes |
| 14926063 | METHODS FOR THE PREPARATION OF RIBOSIDES | October 2015 | September 2018 | Allow | 34 | 4 | 0 | Yes | No |
| 14818488 | Composition Of Dietary Supplements Based On Apoptosis that Support Optimal Health | August 2015 | April 2023 | Abandon | 60 | 6 | 0 | Yes | No |
| 13523471 | TOPICAL ANTIVIRAL FORMULATIONS | June 2012 | December 2013 | Abandon | 18 | 1 | 0 | No | No |
| 13439324 | PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF | April 2012 | October 2013 | Abandon | 19 | 2 | 0 | No | No |
| 13081068 | GLYCOMIMETIC COMPOUNDS AND METHODS TO INHIBIT INFECTION BY HIV | April 2011 | November 2013 | Abandon | 32 | 1 | 1 | No | No |
| 13073135 | Platycodin Radix Extracts, and Their Use in Treating Disease Conditions Associated with Angiogenesis | March 2011 | October 2013 | Abandon | 31 | 1 | 1 | No | No |
| 12877380 | Pharmaceutical Composition for Treating Cancers | September 2010 | August 2013 | Abandon | 35 | 2 | 1 | No | No |
| 12745459 | PHARMACEUTICAL COMPOSITIONS WITH A MECHANISM OF MULTI-TARGET RECEPTOR RETROACTION FOR TREATING DEPRESSION | August 2010 | September 2013 | Abandon | 40 | 2 | 0 | No | No |
| 12809894 | Alkylene Oxide Adducts of Oligosaccharides | June 2010 | July 2013 | Abandon | 37 | 2 | 1 | No | No |
| 12680995 | NOVEL CHONDROITIN SULFATE HAVING DECREASED MOLECULAR WEIGHT AND USE THEREOF | June 2010 | August 2013 | Abandon | 40 | 2 | 0 | No | Yes |
| 12755558 | HIV Treatment | April 2010 | September 2012 | Abandon | 30 | 2 | 1 | Yes | No |
| 12519818 | SYNTHETIC LIPOPHILIC INOSITOL GLYCANS FOR TREATMENT OF CANCER AND GLUCOSE-METABOLISM DISORDERS | April 2010 | July 2013 | Abandon | 49 | 2 | 1 | No | No |
| 12703988 | PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF | February 2010 | June 2013 | Abandon | 40 | 2 | 1 | Yes | No |
| 12309467 | HYALURONIC ACID DISPERSION, PRODUCTION AND USE | February 2009 | June 2013 | Abandon | 53 | 3 | 0 | No | No |
| 10757233 | Prophylactic and therapeutic treatment of infectious and other diseases with mono-and disaccharide-based compounds | January 2004 | April 2007 | Abandon | 39 | 1 | 0 | Yes | No |
| 10661386 | Compositions and methods for treatment of cancer | September 2003 | July 2007 | Abandon | 46 | 1 | 1 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner JIANG, SHAOJIA A.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 0.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner JIANG, SHAOJIA A works in Art Unit 1623 and has examined 45 patent applications in our dataset. With an allowance rate of 4.4%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 39 months.
Examiner JIANG, SHAOJIA A's allowance rate of 4.4% places them in the 1% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by JIANG, SHAOJIA A receive 2.22 office actions before reaching final disposition. This places the examiner in the 57% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by JIANG, SHAOJIA A is 39 months. This places the examiner in the 25% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +20.0% benefit to allowance rate for applications examined by JIANG, SHAOJIA A. This interview benefit is in the 62% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.
When applicants file an RCE with this examiner, 12.5% of applications are subsequently allowed. This success rate is in the 9% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 16.7% of cases where such amendments are filed. This entry rate is in the 20% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.
When applicants file petitions regarding this examiner's actions, 88.9% are granted (fully or in part). This grant rate is in the 88% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 1% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 1% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.